TY  - JOUR
TI  - Highly effective treatment options for rheumatoid arthritis afforded by the availability of biosimilars
AU  - Shea, Leticia A.
AU  - Ahmed, Jamshaid S.
PY  - 2025
JO  - Exploration of Musculoskeletal Diseases
VL  - 3
SP  - 100787
DO  - 10.37349/emd.2025.100787
UR  - https://www.explorationpub.com/Journals/emd/Article/100787
AB  - Biosimilars are biologic products that provide equal mechanisms and efficacy to that of their original biologic references. This paper aims to provide a comprehensive overview of the numerous ways biosimilars are improving care for individuals living with rheumatoid arthritis (RA), from the effective application of biosimilars in treatment-naive RA patients, switching from an original biologic to a biosimilar, to the ability to tailor biologic therapy in respect to mechanisms provided by different biologic classes. Biosimilars provide a significant reduction in cost and provide patients with treatment options that do not exhibit adverse drug reactions (ADRs) as exhibited with methotrexate and other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Understanding mechanisms to discern patient response to biologic therapies will gain increasing importance as biosimilars with different targeted mechanisms enter the market. Patients who do not respond to one class of biologic medicine now have alternative biosimilars available to support their care. Study results support that patients initiated on biosimilars stay on biosimilars, so it is prudent to remain aware of the biosimilars available and candidates in development.
ER  -